Genfit
Open
BrancheGesundheitswesen
13.06 0.31
Übersicht
Veränderung der Aktienkurses
24h
Min
12.76
Max
13.44
Einkommen | -76M |
|---|---|
Verkäufe | 32M |
EPS | -1.525 |
Gewinnspanne | -237.939 |
Angestellte | 188 |
EBITDA | -7M |
Nächstes Ergebnis | 29. Sept. 2026 |
|---|
Marktkapitalisierung | 674M |
|---|---|
Vorheriger Eröffnungskurs | 12.75 |
Vorheriger Schlusskurs | 13.06 |
Nachrichtenstimmung
By Acuity
65%
35%
302 / 342 Ranking in Healthcare
Genfit Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Genfit Prognose
Stimmung
By Acuity
302 / 342 Ranking in Gesundheitswesen
Nachrichtenstimmung
Bärische Evidenz
Volatilität
Unterdurchschnittlich
Nachrichtenvolumen (RCV)
Überdurchschnittlich
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.